Kaneka Americas Holding, Inc.
Was created on April 1, 2012, to:
- Provide a more independent management structure for Kaneka business operations in North and South America
- Provide management and structural support for growth of the business portfolio.
- Create consistent policies and services for the group companies in general areas such as compliance, governance, legal support, etc.
Kaneka North America LLC
A subsidiary of Kaneka Americas Holding, Inc was created on April 1, 2012, by the merger of Kaneka Texas Corporation and Kaneka Nutrients L.P.
Kaneka Texas Corporation (KTC): Founded in 1982 as a wholly owned subsidiary of Kaneka Corporation, the plant is located southeast of Houston in the Bayport Industry District at 6161 Underwood Road, Pasadena, TX. KTC started manufacturing operations in 1984 making impact modifier, Kane Ace B, for the plastic industry. Major additions to this plant occurred in 1987 and 1993, making it the largest modifier plant in the world.
In 1990 production of polyimide film began at this site. In 2008 KTC began manufacture of CPVC resin and in 2009 the MS Polymer facility began producing the first liquid polymer products at this site.
Kaneka Nutrients L.P.: Since 2006 KNL has been manufacturing an array of unique nutritional ingredients for the supplement and food & beverages industries. Kaneka is the largest manufacturer of CoQ10 in the world, and the only company that manufactures CoQ10 in the U.S. since 1997. It is the primary brand of CoQ10 used in FDA-approved National Institutes of Health-funded clinical trials, and has been used in the vast majority of all other clinical trials over the past 30 years. The facility is located at 6250 Underwood Rd., Pasadena, TX.
Kaneka Pharma America LLC
Kaneka Pharma America LLC is a wholly owned subsidiary of Kaneka Americas Holdings, Inc. Established in 1997, KPA has a head office in New York, N.Y. with a sales office in Torrance, C.A. KPA is the exclusive distributor in the U.S. and Canada for the extracorporeal LDL-apheresis system, Liposorber, manufactured by Kaneka Corporation. It also markets vascular interventional devices in North & South American countries. A new device in the ophthalmology field is scheduled for its market launch in 2012. In addition, emerging devices in the field of cardiology, neurology, nephrology, and regenerative medicine are under development with the aim of patients’ improved outcome.